NOW-HEALTH-INTERNATIONAL
7.6.2021 10:02:06 CEST | Business Wire | Press release
Now Health International Group, a leading International Private Medical Insurance (IPMI) provider, has announced a new program with Starr Insurance Companies, a leading global insurance company, to drive forward ambitious growth plans in Europe.
This mutually beneficial relationship combines Now Health International’s global presence and expertise in providing high quality international health insurance solutions and state of the art digital tools, including the recently launched Mobile Pass innovation, with Starr’s long-standing global knowledge and ability to deliver customised solutions across Europe through a specialised team of professionals dedicated to offering the best service to its customers.
Under the new agreement, as of 1st March 2021, Starr Insurance Companies will insure all new and renewing business across Europe. Now Health International will continue to administer the international health insurance plans, including claims handling and customer service support. All members will also continue to benefit from access to Now Health International’s award-winning digital tools.
Zahir Sharif, Managing Director, Now Health International said, “At Now Health International we are committed to further building our presence in Europe and have ambitions to expand into new markets across the region. Starr Insurance Companies, with over 100-years of heritage, expertise and existing presence across global markets, is a well-placed partner to help us achieve this goal.”
Now Health International will continue to offer its existing products to members across Europe under the new partnership, including its flagship, benefit-rich WorldCare product, and its more affordable SimpleCare product for those looking for essential health cover. There will be no changes to plan benefits, pricing, or the customer service experience as a result of this arrangement.
The new program replaces Now Health International’s previous relationship with AXA PPP Healthcare. To ensure a smooth transition process for existing members, a runoff period will be deployed until 31st December 2021, seamlessly transitioning members to the new arrangement with Starr Insurance Companies at their next plan renewal.
Michel Faucher, Chief Commercial Officer, Now Health International added, “We are very excited about our new relationship and the opportunities it presents for us in the long term. I also want to reassure our members and partners that there will be complete continuity under the new arrangements, with the same market-leading plans and benefits, high standards of service, and state of the art digital tools our European customer base have come to expect.”
Santiago Mora, Head of International Accident & Health for Starr, said, “We’re excited to be the insurance provider for Now Health International, one of the fastest growing providers of medical insurance solutions for global expatriates.”
-ENDS-
Notes to Editors: About Now Health International Group
The Now Health International Group consists of Now Health International and Best Doctors Insurance. Now Health International is one of the fastest growing providers of International Private Medical Insurance (IPMI) solutions for Global Expatriates, High-Net-Worth individuals and Companies. Now Health has offices in the UK, Malta, UAE, China, Hong Kong, Singapore and Indonesia. Best Doctors Insurance is a Bermuda/ Miami based major medical insurance provider with offices in the US, Canada and Ecuador and distribution throughout Central and Latin America, the Caribbean and Canada.
The combined business is a global top tier specialist IPMI provider, with complementary products, distribution and geographies. The operation spans four continents, with 11 sales &/or service offices, 125,000+ members, 370+ employees and 5,000+ distribution partners.
Notes to Editors: About Starr Insurance Companies
Starr Insurance Companies (or Starr) is a marketing name for the operating insurance and travel assistance companies and subsidiaries of Starr International Company, Inc. and for the investment business of C. V. Starr & Co., Inc. and its subsidiaries. Starr is a leading insurance and investment organization with a presence on six continents; through its operating insurance companies, Starr provides property, casualty, and accident and health insurance products as well as a range of specialty coverages including aviation, marine, energy and excess casualty insurance. Starr’s insurance company subsidiaries domiciled in the U.S., Bermuda, China, Hong Kong, Singapore, U.K. and Malta each have an A.M. Best rating of “A” (Excellent). Starr’s Lloyd’s syndicate has a Standard & Poor’s rating of “A+” (Strong).
View source version on businesswire.com: https://www.businesswire.com/news/home/20210607005024/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
